Pfizer Restructures Leadership with Chris Boshoff as New R&D Chief Amidst Strategic Oncology Focus

Chris Boshoff has been appointed as Pfizer's new Chief Scientific Officer, slated to take on the role from January 1, 2024. Having previously served as the Chief Oncology Officer and Executive Vice President, Boshoff brings a wealth of experience to his new position, highlighted by his instrumental role in developing 24 medicines across 30 indications during his 11 years at Pfizer[1][2]. His appointment comes amidst pressure from activist investors, with expectations to rejuvenate Pfizer's R&D strategy, notably in oncology, a focus area for Pfizer as they aim to expand their cancer drugs portfolio[2][3]. Albert Bourla, Pfizer's CEO, commended Boshoff for his leadership, which has significantly contributed to the productivity of the oncology division, setting a strong foundation for future breakthroughs[1].